Catalent, Inc. (NYSE:CTLT) Receives Consensus Rating of “Hold” from Brokerages

Catalent, Inc. (NYSE:CTLT) has been given an average recommendation of “Hold” by the seven analysts that are currently covering the company, Marketbeat.com reports. Seven investment analysts have rated the stock with a hold recommendation. The average 1-year price objective among analysts that have covered the stock in the last year is $63.40.

CTLT has been the subject of several analyst reports. StockNews.com assumed coverage on Catalent in a research note on Friday. They issued a “hold” rating for the company. Baird R W cut Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. William Blair reiterated a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Finally, Robert W. Baird reiterated a “neutral” rating and issued a $63.50 price objective on shares of Catalent in a research note on Tuesday, September 24th.

Insider Buying and Selling at Catalent

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of Catalent stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the sale, the director now owns 10,835 shares of the company’s stock, valued at approximately $646,849.50. The trade was a 20.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Principal Financial Group Inc. boosted its holdings in Catalent by 0.6% in the 2nd quarter. Principal Financial Group Inc. now owns 207,977 shares of the company’s stock worth $11,695,000 after buying an additional 1,283 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in shares of Catalent by 63.1% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 842,136 shares of the company’s stock valued at $47,353,000 after acquiring an additional 325,746 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd increased its holdings in shares of Catalent by 1.4% in the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,238 shares of the company’s stock valued at $1,082,000 after acquiring an additional 257 shares during the period. MUFG Securities EMEA plc purchased a new stake in shares of Catalent during the second quarter valued at about $13,596,000. Finally, Picton Mahoney Asset Management acquired a new position in shares of Catalent during the second quarter worth $2,811,000.

Catalent Price Performance

Shares of CTLT opened at $63.48 on Friday. The business’s fifty day moving average is $60.76 and its 200 day moving average is $59.49. Catalent has a 12-month low of $41.15 and a 12-month high of $63.50. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. The stock has a market cap of $11.52 billion, a P/E ratio of -28.09, a P/E/G ratio of 2.70 and a beta of 1.15.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same quarter in the prior year, the business earned ($0.10) earnings per share. The firm’s quarterly revenue was up 4.2% compared to the same quarter last year. Sell-side analysts anticipate that Catalent will post 0.78 earnings per share for the current fiscal year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.